BullFrog AI’s Collaboration with Lieber Institute for Brain Development Yields Potentially Groundbreaking Biological Stratification of Brain Expression Data
GAITHERSBURG, Md., Jan. 17, 2024 (GLOBE NEWSWIRE) — BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced early results from its collaboration with the Lieber Institute for Brain Development (LIBD) that could revolutionize the understanding and treatment of psychiatric disorders. The early findings from this global strategic partnership have successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.
Related news for (BFRG)
- MoBot’s Stock Market Highlights – 10/08/25 11:00 AM
- BullFrog AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks™ to Global Biopharma Clients
- Join Bullfrog AI’s Exclusive Live Investor Webinar and Q&A Session on April 23
- Don’t Miss Out: MoBot’s Latest Stock Updates 04/11/25 03:00 PM
- Today’s Top Performers: MoBot’s Market Review 04/11/25 02:00 PM